1. Home
  2. CYN vs TVRD Comparison

CYN vs TVRD Comparison

Compare CYN & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cyngn Inc.

CYN

Cyngn Inc.

HOLD

Current Price

$1.20

Market Cap

22.9M

Sector

Technology

ML Signal

HOLD

TVRD

Tvardi Therapeutics Inc.

HOLD

Current Price

$2.36

Market Cap

25.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYN
TVRD
Founded
2013
2017
Country
United States
United States
Employees
62
12
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.9M
25.0M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
CYN
TVRD
Price
$1.20
$2.36
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$29.50
AVG Volume (30 Days)
222.3K
54.3K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$368,138.00
N/A
Revenue This Year
$3,359.28
N/A
Revenue Next Year
$347.47
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.10
$2.34
52 Week High
$17.20
$43.65

Technical Indicators

Market Signals
Indicator
CYN
TVRD
Relative Strength Index (RSI) 38.95 29.35
Support Level N/A N/A
Resistance Level $1.76 $4.42
Average True Range (ATR) 0.08 0.20
MACD 0.00 -0.02
Stochastic Oscillator 38.89 6.08

Price Performance

Historical Comparison
CYN
TVRD

About CYN Cyngn Inc.

Cyngn Inc is an industrial autonomous vehicle technology company, focused on addressing industrial uses for autonomous vehicles. It develops full-stack autonomous driving software, DriveMod, which is integrated into vehicles manufactured by original equipment manufacturers during the assembly process. The company designs its software to be compatible with a range of sensors and hardware components and integrates it with its own systems to enable autonomous vehicle functionality.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Share on Social Networks: